VELA Investment Management LLC Acquires 44,855 Shares of PROCEPT BioRobotics Corporation $PRCT

VELA Investment Management LLC grew its stake in shares of PROCEPT BioRobotics Corporation (NASDAQ:PRCT) by 61.4% in the second quarter, Holdings Channel reports. The firm owned 117,894 shares of the company’s stock after acquiring an additional 44,855 shares during the period. VELA Investment Management LLC’s holdings in PROCEPT BioRobotics were worth $2,662,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Johnson & Johnson bought a new stake in PROCEPT BioRobotics during the 2nd quarter valued at about $8,082,263. Pinnacle Associates Ltd. purchased a new stake in PROCEPT BioRobotics in the 4th quarter valued at about $3,876,000. DNB Asset Management AS grew its stake in PROCEPT BioRobotics by 213.9% in the 4th quarter. DNB Asset Management AS now owns 99,567 shares of the company’s stock worth $3,132,000 after acquiring an additional 67,848 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. grew its stake in PROCEPT BioRobotics by 69.8% in the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 174,739 shares of the company’s stock worth $5,375,000 after acquiring an additional 71,832 shares in the last quarter. Finally, Quantinno Capital Management LP purchased a new position in shares of PROCEPT BioRobotics during the first quarter worth approximately $1,693,000. 89.46% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

PRCT has been the subject of a number of research reports. Piper Sandler lowered their price target on PROCEPT BioRobotics from $35.00 to $25.00 and set an “overweight” rating for the company in a report on Wednesday, August 5th. Wells Fargo & Company downgraded PROCEPT BioRobotics from an “overweight” rating to an “equal weight” rating and set a $19.00 price objective on the stock. in a report on Wednesday, August 5th. Citigroup lowered PROCEPT BioRobotics to a “hold” rating in a research report on Thursday, July 2nd. TD Cowen lowered their target price on PROCEPT BioRobotics from $34.00 to $28.00 and set a “buy” rating for the company in a report on Wednesday, August 5th. Finally, Truist Financial set a $21.00 price objective on shares of PROCEPT BioRobotics in a research note on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, ten have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $25.09.

PROCEPT BioRobotics Stock Performance

NASDAQ PRCT opened at $22.76 on Monday. The company has a quick ratio of 5.35, a current ratio of 6.55 and a debt-to-equity ratio of 0.15. The firm has a market cap of $1.30 billion, a PE ratio of -11.73 and a beta of 0.91. The company has a 50 day moving average price of $20.35 and a 200 day moving average price of $23.66. PROCEPT BioRobotics Corporation has a 52 week low of $16.67 and a 52 week high of $41.51.

PROCEPT BioRobotics (NASDAQ:PRCT) last announced its earnings results on Tuesday, August 4th. The company reported ($0.47) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($0.01). PROCEPT BioRobotics had a negative net margin of 32.53% and a negative return on equity of 30.62%. The firm had revenue of $94.50 million during the quarter, compared to analyst estimates of $92.77 million. During the same quarter last year, the business earned ($0.35) earnings per share. PROCEPT BioRobotics’s revenue was up 19.3% on a year-over-year basis. As a group, sell-side analysts forecast that PROCEPT BioRobotics Corporation will post -1.67 EPS for the current fiscal year.

PROCEPT BioRobotics News Roundup

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Positive Sentiment: The stock’s increase suggests investors may be treating the latest announcements as repetitive legal notices rather than a new deterioration in the company’s business. The reports did not announce a judgment, settlement, regulatory penalty, or additional financial charge.
• Neutral Sentiment: Multiple firms—including Kaplan Fox class action deadline Kaplan Fox, Hagens Berman investor deadline Hagens Berman, and Rosen Law investor deadline Rosen Law—reminded investors that September 22, 2026 is the deadline to seek lead-plaintiff status. The proposed class covers purchases made from February 28, 2024, through February 25, 2026.
• Negative Sentiment: The lawsuit alleges that PROCEPT made misleading statements or failed to disclose repeated weakness in unit handpiece sales and excess customer inventory, allegedly caused in part by late-quarter bulk discounts. Law firms say these issues contributed to a substantial stock decline, including an approximately 18% drop cited in the filings. The allegations remain unproven, but continued litigation could increase costs, management distraction, and investor uncertainty. Hagens Berman securities fraud lawsuit

Insider Buying and Selling at PROCEPT BioRobotics

In other PROCEPT BioRobotics news, CEO Larry Wood bought 23,900 shares of PROCEPT BioRobotics stock in a transaction that occurred on Friday, August 7th. The shares were bought at an average cost of $20.85 per share, with a total value of $498,315.00. Following the transaction, the chief executive officer directly owned 23,900 shares of the company’s stock, valued at approximately $498,315. This represents a ? increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 4.00% of the stock is owned by insiders.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.